전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved20 programs
AntibodyCurated CorestaleEpizyme, Inc.Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#BioJungboMoa-pick#monoclonal-antibody+4
Trials 49Status Recruiting
AntibodyLimited DatastaleEpizyme, Inc.Phase 2

Tafasitamab (Tafasitamab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase2#monoclonal-antibody#RelapsedHematologicMalignancy+3
Trials 48Status Discontinued
CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 17Status Discontinued
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf)

Advanced Unresectable or Metastatic Solid Malignancy · Advanced Unresectable or Metastatic Soli

#AdvancedUnresectableorMetastatic#Antibody#Phase2#monoclonal-antibody#Roche
Trials 15Status Active
AntibodyLimited DatastaleAntengene Therapeutics LimitedPhase 1

nivolumab (Opdivo, ATG-017+Nivolumab)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase1#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Discontinued
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous CCR4 CAR T cells (Autologous CCR4 CAR T cells)

Relapsed and/or Refractory Mature T Cell Malignancy; Peripheral T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleMarcela V. Maus, M.D.,Ph.D.Phase 1

CAR-37 T cells (CAR-37 T cells)

Hematologic Malignancy; Leukemia · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD123-CD33 cCAR T cells (CD123-CD33 cCAR T cells)

Hematologic Malignancy; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleSt. Jude Children's Research Ho…Phase 1

Autologous (CD70-CAR T cell infusion, CD70-CAR T cell infusion (Autologous))

Hematologic Malignancy; ALL, Childhood · Hematologic Malignancy

#HematologicMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CLL1-CD33 cCAR T cells (CLL1-CD33 cCAR T cells)

Hematologic Malignancy; Acute Myeloid Leukemia · CD33

#CD33#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

Commercial CAR-T (Commercial CAR-T)

Malignancy; Cancer · Malignancy

#Malignancy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
AntibodyLimited DatastaleJanssenPhase 1

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Darzalex Faspro (Daratumumab and hyaluronidase-fihj))

Hematologic Malignancy; Bone Marrow Transplant Rejection · Hematologic Malignancy

#HematologicMalignancy#Antibody#Phase1#monoclonal-antibody#BoneMarrowTransplantRejection+1
Trials 1Status Recruiting
CGTLimited DatastaleUNC Lineberger Comprehensive Ca…Phase 2

Investigational CAR-T (Investigational CAR-T)

Malignancy; Cancer · Malignancy

#Malignancy#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleShanghai Longyao Biotechnology …Phase 2

Mixed CD19/CD20 CAR-T Transfer (Mixed CD19/CD20 CAR-T Transfer)

Recurrent or Refractory B Cell Malignancy · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleSCRI Development Innovations, L…Phase 1

PTK787/ZK222584 and Bevacizumab (PTK787/ZK222584 and Bevacizumab)

Refractory Malignancy; Advanced Malignancies · FRα

#FR#Antibody#Phase1#monoclonal-antibody#RefractoryMalignancy+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART19 cells (ThisCART19 cells)

B Cell Malignancy · B Cell Malignancy

#BCellMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleFundamenta Therapeutics, Ltd.Phase 1

ThisCART22 cells (ThisCART22 cells)

B-cell Malignancy · B-cell Malignancy

#B-cellMalignancy#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleChinese PLA General HospitalPhase 2

metoprolol, infliximab, etanercept, tocilizumab and/or other agents (metoprolol, infliximab, etanercept, tocilizumab and/or other agents)

Solid Tumor; Hematological Malignancy · Solid Tumor

#SolidTumor#Antibody#Phase2#monoclonal-antibody#HematologicalMalignancy+1
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, tremelimumab + durvalumab)

Advanced Malignancy · Advanced Malignancy

#AdvancedMalignancy#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Active
AntibodyLimited DatastaleAIDS Malignancy ConsortiumPhase 2

yttrium Y 90 ibritumomab tiuxetan (yttrium Y 90 ibritumomab tiuxetan)

AIDS-related Lymphoma; Adult Non-Hodgkin's Lymphoma · AIDS-related Lymphoma

#AIDS-relatedLymphoma#Antibody#Phase2#monoclonal-antibody#AdultNon-HodgkinsLymphoma+1
Trials 1Status Discontinued